AN2 Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
AN2 reported Q2 2026 net loss of $8.2M (vs. $6.5M in Q2 2025) with R&D expenses of $6.0M (vs. $3.2M). The company is advancing Phase 2 studies in polycythemia vera (oral epetraborole), M. abscessus lung disease (investigator-initiated, 84-patient trial), and chronic Chagas disease (AN2-502998, Phase 2 planned by year-end 2026). Cash and investments totaled $79.9M at June 30, 2026, with projected runway into 2029. The company also declared a development candidate for solid tumors (ENPP1) and plans to advance a second oncology candidate by end of 2026.
Why this rating
Meaningful pipeline progression (three Phase 2 programs active by year-end) and 3+ year cash runway are significant for a $23.1M market-cap company. However, clinical-stage biotech success is inherently uncertain; no new financing, partnership, or clinical data readout occurred. Q2 losses increased 26% YoY, eroding runway relative to company size.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.